QUOTE AND NEWS
Benzinga  Feb 13  Comment 
Novartis AG (ADR) (NYSE: NVS) obtained approval for an accelerated review of an experimental heart-failure treatment Friday, while Pfizer Inc. (NYSE: PFE)'s new formulation of oxycondone aimed at foiling abuse won acceptance for an...
Forbes  Jan 29  Comment 
As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money.  So let's look at two noteworthy recent insider buys.
Benzinga  Jan 20  Comment 
Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced dosing of the first patient in a new clinical trial evaluating the combination of VS-5584, its...
Forbes  Dec 29  Comment 
Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is that they...
Benzinga  Nov 10  Comment 
Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced today that Robert Forrester, Verastem President and Chief Executive Officer, will participate in a...
StreetInsider.com  Oct 24  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Verastem+%28VSTM%29+Issues+Encouraging+Update+on+VS-6063+in+Reducing+Cancer+Stem+Cell+Markers/9938814.html for the full story.
DailyFinance  Jun 24  Comment 
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced publication of an article titled “FAK Inhibitor Kills Mesothelioma...
Motley Fool  Jun 21  Comment 
Verastem might have to compete with GlaxoSmithKine, but Eli Lilly won't be a problem since it's targeting patients that have already taken Lilly's drug.
StreetInsider.com  May 12  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Verastem%2C+Inc.+%28VSTM%29+Will+Expand+COMMAND+into+Japan/9470757.html for the full story.




 

Verastem (NASDAQ:VSTM) is a biopharmaceutical company which is developing small moleculre drugs to target cancer stem cells. The company believes that cancer stem cells are a key reason to the recurrence of tumors. These cells are resistant to chemotherapy and other cancer therapies. Verastem's drug will use small molecule compounds to directly target these cancer stem cells. [1]

Business Overview

Verastem is a prerevenue company. For the nine months ended in September of 2011, the company reported a net loss of $8M.[2]

New Updates

The company's initial public offering of stock on the NASDAQ occurred on January 26, 2012. The company offered 5.5M shares each for $10. This was within the $9-$11 initial price range. The deal raised a total of $55M. The lead mangers of the deal were UBS and Leerink Swann.[3]

Trends & Forces

A Prerevenue R&D

At the time of its IPO, Verastem was early in its drug development stage. As a result, the company will have to successfully discover, receive approval, and commercialize a drug based on the money it has. If it fails to do that, it will have to find some other way to generate a cash flow. Because a drug like the one Verastem plans to discover has never been commercialized it is unclear if it is possible or if the FDA would approve it.[4]

  1. VSTM S-1/A 2011 PROSPECTUS SUMMARY "Overiew" pg.1-2
  2. VSTM S-1/A 2011 PROSPECTUS SUMMARY "Selected financial data" pg.48
  3. Renaissance Capital - IPO Home "Verastem prices upsized IPO at $10 midpoint" Jan 26 2012
  4. VSTM S-1/A 2011 PROSPECTUS SUMMARY "Risk factors" pg.11
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki